Idiopathic Parkinson Disease Clinical Trial
Official title:
A First-in-human, Double-blind, Placebo-controlled, Multicentre, Cross-over, Phase I Study to Assess Safety and Tolerability of Repeat Oral Administrations of MRx0029 OR MRx0005 in Adult Participants With Idiopathic Parkinson's Disease
Verified date | April 2023 |
Source | 4D pharma plc |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This is a first-in-human study to evaluate the safety and tolerability of repeat oral administrations of MRx0029 (20 participants) or MRx0005 (20 participants) in participants diagnosed with idiopathic PD. Participants who are successfully screened will be randomized to 1 of 2 treatment sequences (TS) within their cohort (10 participants per sequence). Each treatment period will be separated by a washout period of 4 to 6 weeks. Cohort A Treatment Sequence 1: MRx0029 (1 capsule bid) for 4 weeks; 4-to 6-week washout period; placebo (1 capsule bid) for 4 weeks. Cohort A Treatment Sequence 2: Placebo (1 capsule bid) for 4 weeks; 4-to 6-week washout period; MRx0029 (1 capsule bid) for 4 weeks. Cohort B Treatment Sequence 1 MRx0005 (1 capsule bid) for 4 weeks; 4- to 6-week washout period; placebo (1 capsule bid) for 4 weeks. Cohort B Treatment Sequence 2: Placebo (1 capsule bid) for 4 weeks; 4-to 6-week washout period; MRx0005 (1 capsule bid) for 4 weeks Cohort A will be randomized first and when all participants have been randomized to Cohort A, Cohort B enrollment will begin.
Status | Withdrawn |
Enrollment | 0 |
Est. completion date | April 2023 |
Est. primary completion date | April 2023 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 40 Years to 85 Years |
Eligibility | Inclusion Criteria: 1. Diagnosis of idiopathic PD according to the UKPDS-BBCDC 2. Able to understand and willing to provide informed consent and able to comply with the study procedures and restrictions. 3. Male or female participants age = 40 or = 85 years of age. 4. BMI = 18.0 to = 35.0 kg/m2, inclusive, where BMI (kg/m2) is calculated by body weight (kg)/height2 (m2). 5. Hoehn & Yahr (H&Y) Stage I to II (if on levodopa the participant should be classed as Stage I to II in an 'ON' period) 6. A documented diagnosis of PD 7. If presently being medically treated for PD, they should be on a stable dose unchanged within the 30 days prior to screening and not be expected to require any adjustments or start any new PD medication for the duration of their participation in the study. 8. No clinically relevant abnormal medical history, or abnormal findings on physical examination, vital signs, ECG, or laboratory tests 9. Has been fully vaccinated with an approved Covid-19 vaccine 10. Male and female participants are eligible to enter provided they follow the contraception criteria for the study. Exclusion Criteria: 1. Participants with significant motor fluctuations 2. Parkinson syndromes 3. Known carriers of familial PD genes 4. History and/or current presence of clinically significant CNS disease other than PD. 5. Montreal Cognitive Assessment (MoCA) <24 6. No history of spontaneous constipation since diagnosis 7. Participants who are <70% compliant to completing their e-daily assessed at Treatment Period 1, Day 1. 8. Are non-compliant with prescribed PD medication 9. Comorbidities that have not been optimally controlled for the last 3 months prior to screening. 10. Participants with known Type 1 or Type 2 diabetes mellitus or a HbAlc result. indicative of diabetes/pre-diabetes. 11. Have an active or recent malignant disease or any concomitant end-stage organ disease. 12. Participants with known GI fistula, feeding tubes, or inflammatory bowel disease. 13. Participants who had recent abdominal surgery (6 months before the screening visit). 14. Participants with GI disease resulting in an inability to take oral medication, malabsorption syndrome, prior surgical procedures affecting absorption, uncontrolled GI disease 15. Participants with conditions that may increase the risk of generalized peritonitis 16. Dysphagia to the extent it would affect the participant's ability to swallow the IMP during their participation 17. Anything which in the opinion of the investigator prevents the participant being able to give urine or stool samples. 18. Positive serology for hepatitis B surface antigen (HBsAg), hepatitis C virus antibody (anti-HCV), or human immunodeficiency virus antibodies (anti HIV) 1/2 at screening. 19. Previous history or current active tuberculosis (TB), or taking medication for the treatment of TB. 20. Participant has severe or moderate renal impairment (defined as creatinine clearance <60 mL/min) estimated using Cockcroft-Gault Equation. 21. Participants taking anti-cholinergic medication or amantadine. 22. Participants with congenital, acquired or drug-related immunodeficiency. 23. Participants who use systemic corticosteroids or systemic immunosuppressants for any reason within 30 days prior to screening. 24. Participants taking ad hoc anti-inflammatory medication within 30 days of screening are excluded. 25. Participants taking dopamine antagonists, such as the neuroleptics or metoclopramide are excluded. 26. Participants who are allergic to the following antibiotics: amoxicillin/clavulanic acid, ampicillin, chloramphenicol, clarithromycin, clindamycin, imipenem, or metronidazole. 27. Participants who have completed a course of systemic antibiotics in the 30 days prior to screening. 28. Participants using prebiotic and probiotic supplements 29. Donation or loss of 500 mL blood during the 3 months before screening. 30. Current or history of alcohol or drug abuse or other dependence (except nicotine dependence) within the last 2 years prior to IMP administration. 31. Positive urine drug screen (if not due to concomitant medication) or alcohol breath test. 32. Receipt of a positive COVID-19 test result 33. Participant is currently enrolled in or has not yet completed at least 30 days since ending other investigational device or study drug(s), or participant receiving other investigational agent(s). 34. Received a live vaccine within 4 weeks prior to enrolling in this trial or plan for any such vaccination during the trial or within 4 months after study drug administration. Administration of inactivated vaccines (for example, inactivated influenza vaccines is allowed.). 35. Legal incapacity or limited legal capacity. |
Country | Name | City | State |
---|---|---|---|
n/a |
Lead Sponsor | Collaborator |
---|---|
4D pharma plc | ICON plc, Labcorp Drug Development Inc |
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Incidence of treatment-emergent adverse events (TEAEs) | Number of TEAEs after 4-weeks of treatment with MRx0029 vs 4-weeks of placebo in participants with idiopathic PD | Baseline to Follow-up Visit (up to 24 weeks) | |
Primary | Incidence of treatment-emergent adverse events (TEAEs) | Number of TEAEs after 4 weeks of treatment with MRx0005 vs 4-weeks of placebo in participants with idiopathic PD | Baseline to Follow-up Visit (up to 24 weeks) | |
Primary | Incidence of Serious Adverse Events (SAEs) | Number of SAEs after 4 weeks of treatment with MRx0029 vs 4-weeks of placebo in participants with idiopathic PD | Baseline to Follow-up Visit (up to 24 weeks) | |
Primary | Incidence of Serious Adverse Events (SAEs) | Number of SAEs after 4 weeks of treatment with MRx0005 vs 4-weeks of placebo in participants with idiopathic PD | Baseline to Follow-up Visit (up to 24 weeks) |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04202757 -
Intravenous Plasma Treatment for Parkinson's Disease
|
Early Phase 1 | |
Not yet recruiting |
NCT05103618 -
Effect of Meditation and Controls and Subjects With Parkinson's Disease on Brain Activity Measured by fMRI With FDOPA
|
Phase 2 | |
Completed |
NCT03700684 -
Voice Treatment for Parkinson's Disease
|
N/A | |
Completed |
NCT05027620 -
Feasibility of Motor-cognitive Home Training for Parkinson's Disease Using eHealth Technology
|
N/A | |
Completed |
NCT03652363 -
GDNF in ideopathicParkinsons Disease
|
Phase 2 | |
Recruiting |
NCT02960464 -
tDCS for Treatment of Depression in Parkinson's Disease
|
N/A | |
Completed |
NCT05699161 -
Adipose-derived Stromal Vascular Fraction Cells to Treat Parkinson
|
Phase 1/Phase 2 | |
Completed |
NCT03944785 -
Clinical Outcome Assessment of Parkinson's Disease Patients Treated With XADAGO (Safinamide)
|
||
Completed |
NCT01227265 -
Placebo Controlled Study of Preladenant in Participants With Moderate to Severe Parkinson's Disease (P07037)
|
Phase 3 | |
Terminated |
NCT01215227 -
An Active-Controlled Extension Study to NCT01155466 [P04938] and NCT01227265 [P07037] (P06153)
|
Phase 3 | |
Active, not recruiting |
NCT02780895 -
Parkinsonian Brain Repair Using Human Stem Cells
|
Phase 1 | |
Recruiting |
NCT01860794 -
Evaluation of Safety and Tolerability of Fetal Mesencephalic Dopamine Neuronal Precursor Cells for Parkinson's Disease
|
Phase 1/Phase 2 | |
Completed |
NCT02373072 -
A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of PF-06649751 in Subjects With Idiopathic Parkinson's Disease
|
Phase 1 | |
Terminated |
NCT02393027 -
Quantification of Dopamine Active Transporter (DAT) in Humans: Validation of a New Radiophamaceutical, the [18F] LBT-999
|
Early Phase 1 | |
Completed |
NCT02445651 -
Physiological Effects of Nutritional Support in Patients With Parkinson's Disease
|
N/A | |
Completed |
NCT00437125 -
Study on the Tolerability of Duloxetine in Depressed Patients With Parkinson's Disease
|
Phase 4 | |
Completed |
NCT02723396 -
Sleep, Awake & Move - Part I
|
||
Completed |
NCT00599339 -
Transdermal Rotigotine User Surveillance Study
|
||
Suspended |
NCT05471609 -
Sustained Release Oral Formulation for Treatment of Parkinson's Disease
|
Early Phase 1 | |
Completed |
NCT00160576 -
Levetiracetam Treatment in Adult Subjects With Parkinson's Disease Experiencing Troublesome Dyskinesias
|
Phase 2 |